Circular RNA circMET contributes to tamoxifen resistance of breast cancer cells by targeting miR-204/AHR signaling
- 31 July 2022
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 627, 200-206
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Inner Mongolia Autonomous Region
This publication has 19 references indexed in Scilit:
- Breast cancer: Biology, biomarkers, and treatmentsInternational Immunopharmacology, 2020
- Circular RNAs in Cancer: Biogenesis, Function, and Clinical SignificanceTrends in Cancer, 2020
- Noncoding RNAs in gastric cancer: implications for drug resistanceMolecular Cancer, 2020
- Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New BottlesMolecules, 2020
- Exosome‐delivered circRNA promotes glycolysis to induce chemoresistance through the miR‐122‐PKM2 axis in colorectal cancerMolecular Oncology, 2020
- The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinomaMolecular Cancer, 2019
- AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs)Journal of Experimental & Clinical Cancer Research, 2019
- Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancerJournal of Hematology & Oncology, 2018
- Breast Cancer: Multiple Subtypes within a Tumor?Trends in Cancer, 2017
- Breast cancerThe Lancet, 2017